Sergliflozin etabonate

Cat. No.: HY-12611

CAS No.: 408504-26-7

Molecular Formula: $C_{23}H_{28}O_9$

Molecular Weight: 448.46

Target: SGLT

Pathway: Membrane Transporter/Ion Channel

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes[1].

IC_{50} & Target

SGLT2

In Vivo

Sergliflozin etabonate (1, 3, 10, 30 mg/kg; oral; once) significantly reduces non-fasting blood glucose levels in KK-Ay mice in a dose-dependent manner[1].

Sergliflozin etabonate (1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate; fed; daily for 9 weeks) reduces non-fasting blood glucose level and decreases triglyceride content in the liver in a dose-dependent manner in KK-Ay mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	14 weeks, Female KK-Ay mice[1]
Dosage:	1, 3, 10, 30 mg/kg
Administration:	Oral; once
Result:	Significantly reduced non-fasting blood glucose level with the reduction in blood glucose level at 2 h post dosing in the 1 mg/kg group, 3 mg/kg group, 10 mg/kg group, and 30 mg/kg group was 12, 15, 28, and 39%, respectively.

Animal Model:	4 weeks, Female KK-Ay mice[1]
Dosage:	1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate
Administration:	Fed, daily for 9 weeks
Result:	Reduced non-fasting blood glucose level and decreased triglyceride content in the liver in a dose-dependent manner in diabetic control KK-Ay mice.

REFERENCES

[1]. Katsuno K, et al. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol. 2009 Sep 15;618(1-3):98-104.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA